Company profile
Calithera Biosciences, Inc.
OTC: CALA · Healthcare · Biotechnology
#638 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ 32GM —SS 29
v0.1 · 25/100 weight · pillars only
↑ balance-sheet leverage, 3-yr revenue growth · ↓ Piotroski F, disclosure history
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$39.6M
Employees
8
as of 2026-07-12
Market cap
$1.9k
as of 2026-07-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$9.8M$9.8M2021
Net income-$39.6M-$39.6M2022
Operating income-$42.1M-$42.1M2022
Total assets$28.7M$28.7M2022
Liabilities$8.3M$8.3M2022
Equity$20.4M$20.4M2022
Revenue trend
FY2018 – FY2021 · USD
FY18
FY18
FY18
FY18
FY18
FY18
FY18
FY21
Revenue by segment
Filed disclosures · FY2018
By product
License And Service100%
By geography
Not disclosed.
The read
What is Calithera Biosciences, Inc.’s revenue?
Calithera Biosciences, Inc. booked $9.8M in FY2021 revenue, contracting 56% year over year — slower than 83% of Healthcare companies we track, at a -406.7% net margin.
Peers · Healthcare
Syros Pharmaceuticals, Inc.——Stablecoin Development Corp.44DTaysha Gene Therapies, Inc.48DPrecigen, Inc.44DDelivra Health Brands Inc.55CYulong Eco-Materials Limited——Neighbors
San Mateo →Key facts
CEOStephanie Wong
SectorHealthcare
IndustryBiotechnology
HeadquartersSouth San Francisco, CA
ExchangeOTC: CALA
Employees8
IPO date2014-10-02
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.